- Capstone Copper Corp. (CS:CA) Q1 2026 Earnings Call Transcript
Apr 29, 2026 · seekingalpha.com
Capstone Copper Corp. (CS:CA) Q1 2026 Earnings Call Transcript
- European Dividend Stocks To Consider In April 2026
Apr 3, 2026
As European markets experience a wave of optimism, with the STOXX Europe 600 Index rising by 3.92% amid hopes for a short-lived Middle East conflict, investors are keenly observing how inflation and energy costs impact economic forecasts across the region. In this environment, dividend stocks can offer stability and income potential, making them an attractive consideration for those looking to navigate market volatility while benefiting from steady returns.
Top 10 Dividend Stocks In Europe
Name Dividend Yield Dividend Rating Zurich Insurance Group (SWX:ZURN) 4.34% ★★★★★★ Valmet Oyj (HLSE:VALMT) 5.53% ★★★★★★ Teleperformance (ENXTPA:TEP) 9.16% ★★★★★★ Telekom Austria (WBAG:TKA) 4.57% ★★★★★★ Swiss Re (SWX:SREN) 4.83% ★★★★★★ Rubis (ENXTPA:RUI) 5.90% ★★★★★★ HEXPOL (OM:HPOL B) 5.87% ★★★★★★ Evolution (OM:EVO) 5.04% ★★★★★★ DKSH Holding (SWX:DKSH) 4.30% ★★★★★★ Allianz (XTRA:ALV) 4.65% ★★★★★★
Click here to see the full list of 214 stocks from our Top European Dividend Stocks screener.
Let's take a closer look at a couple of our picks from the screened companies.
AL Sydbank
Simply Wall St Dividend Rating: ★★★★★☆
Overview: AL Sydbank A/S, with a market cap of DKK45.87 billion, offers a range of banking products and services to retail clients, corporates, and associations both in Denmark and internationally.
Operations: AL Sydbank A/S generates its revenue from several segments, including Banking (DKK6.30 billion), Treasury (DKK81 million), Sydbank Markets (DKK384 million), and Asset Management (DKK525 million).
Dividend Yield: 4.7%
AL Sydbank's dividend yield is competitive within the Danish market, though its dividend history has been volatile. The recent decrease in dividends to DKK 25 per share reflects this instability. Despite a reasonable payout ratio of 71.4%, earnings have declined, impacting profitability and leading to substantial shareholder dilution over the past year. The company's share repurchase program aims to optimize capital structure, while future earnings are forecasted to cover dividends more sustainably at a lower payout ratio of 50.4%.
Click here to discover the nuances of AL Sydbank with our detailed analytical dividend report. Our expertly prepared valuation report AL Sydbank implies its share price may be lower than expected.CPSE:ALSYDB Dividend History as at Apr 2026
Capgemini
Simply Wall St Dividend Rating: ★★★★☆☆
Overview: Capgemini SE, with a market cap of €17.46 billion, offers consulting, digital transformation, technology, and engineering services across North America, Europe including France and the UK, the Asia-Pacific region, and Latin America.
Operations: Capgemini's revenue is primarily derived from three segments: Operations & Engineering (€6.51 billion), Applications & Technology (€14.15 billion), and Strategy & Transformation (€1.80 billion).
Story Continues
Dividend Yield: 3.3%
Capgemini's dividend payments have grown over the past decade, although they have been volatile with significant annual drops. Despite this instability, dividends are well covered by earnings and cash flows, with a payout ratio of 36% and cash payout ratio of 26.3%. The dividend yield stands at 3.31%, lower than the top quartile in France. Recent strategic partnerships and client agreements aim to enhance its technological offerings, potentially supporting future financial stability.
Click to explore a detailed breakdown of our findings in Capgemini's dividend report. The valuation report we've compiled suggests that Capgemini's current price could be quite moderate.ENXTPA:CAP Dividend History as at Apr 2026
AXA
Simply Wall St Dividend Rating: ★★★★★☆
Overview: AXA SA operates globally through its subsidiaries, providing insurance, asset management, and banking services with a market cap of €83.26 billion.
Operations: AXA SA's revenue segments include AXA XL (€19.74 billion), Europe (€35.59 billion), France (€24.67 billion), and Asia, Africa & EME-LATAM (€13.68 billion).
Dividend Yield: 5.7%
AXA's dividend yield of 5.73% is among the top in France, supported by a reasonable payout ratio of 67.6% and strong cash flow coverage at 21.4%. However, its dividend history has been volatile over the past decade. Recent financial performance shows robust growth, with net income reaching €9.8 billion for 2025, up from €7.89 billion previously. A share repurchase program worth up to €1.25 billion may further enhance shareholder value.
Take a closer look at AXA's potential here in our dividend report. The analysis detailed in our AXA valuation report hints at an deflated share price compared to its estimated value.ENXTPA:CS Dividend History as at Apr 2026
Summing It All Up
Take a closer look at our Top European Dividend Stocks list of 214 companies by clicking here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.
Looking For Alternative Opportunities?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CPSE:ALSYDB ENXTPA:CAP and ENXTPA:CS.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- A Look At AXA (ENXTPA:CS) Valuation After Recent Share Price Pullback
Mar 20, 2026
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
AXA stock performance snapshot
AXA (ENXTPA:CS) has attracted investor attention after recent share price moves, with the stock showing mixed returns over the past week, month and past 3 months against a backdrop of steady reported revenues and profits.
See our latest analysis for AXA.
At a share price of €38.44, AXA has seen a 6.7% 3 month share price pullback. However, the 1 year total shareholder return of 2.16% and 5 year total shareholder return of 130.14% highlight a stronger longer term picture.
If AXA’s mixed momentum has you thinking about diversification, it could be a good moment to scan for other ideas using the 98 top founder-led companies
With AXA trading at €38.44, and with an indicated discount to some valuation estimates, the key question now is whether the stock is meaningfully undervalued or if the market is already pricing in future growth.
Most Popular Narrative: 16.5% Undervalued
AXA’s most followed valuation narrative puts fair value at €46.05, above the current €38.44 share price, framing the stock as materially underpriced on those assumptions.
Strong momentum in digitalization, AI adoption, and streamlined direct distribution (bolstered by the Prima acquisition) is expected to drive future cost efficiencies, improved customer acquisition, and expanded market share among digitally savvy, price-sensitive, and underserved customer segments, supporting higher future revenue growth and net margins.
Read the complete narrative.
Curious what kind of revenue growth, margin profile and earnings multiple are baked into that fair value figure? The narrative connects all three in a tight equation that could materially influence how AXA’s long term earnings power and rerating potential are viewed.
The valuation work behind this narrative uses a 6.29% discount rate and links AXA’s fair value to projected gains in profitability, scale and earnings quality rather than a simple market multiple comparison.
Result: Fair Value of €46.05 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on execution. Softer reinsurance pricing and ambitious cost saving and digital plans both carry clear potential to derail the upbeat valuation story.
Find out about the key risks to this AXA narrative.
Next Steps
Given the mix of optimism and caution so far, it makes sense to review the numbers and form your own view quickly. Start with the 4 key rewards and 1 important warning sign.
Story Continues
Looking for more investment ideas?
If you stop at AXA, you risk missing out on other opportunities that match your goals, so use the tools available and widen your watchlist smartly.
Target income first by scanning for companies that have paid-out strength with the 471 dividend fortresses. Hunt for value by checking companies that pair quality fundamentals with attractive pricing through the 223 high quality undervalued stocks. Prioritise resilience by focusing on businesses with strong financial footing using the solid balance sheet and fundamentals stocks screener (383 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CS.PA.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- Executive optimism on US economy rises in Q1 AICPA-CIMA survey
Mar 6, 2026
Business leaders became more optimistic about the US economy in the first three months of this year, according to the first‑quarter (Q1) American Institute of Certified Public Accountants (AICPA) and Chartered Institute of Management Accountants (CIMA) Economic Outlook Survey.
The survey, conducted on 3–24 February 2026, includes 236 qualified responses from AICPA members in executive roles in business and industry.
In the latest poll, 39% of respondents said they are optimistic about the US economy over the next 12 months, an increase from 28% reported in the previous quarter.
Views on company‑level prospects also improved.
Executives expressing optimism about their own organisations increased to 47% in Q1, up from 41% in Q4 last year.
Some 55% of executives now expect their businesses to grow this quarter, compared with 48% who said the same three months earlier.
Domestic economic conditions remained the most frequently cited issue for respondents.
Concerns about employee and benefits costs climbed into second place, while spending on materials, supplies and equipment moved into third. Reports of inflation as a primary concern eased during the quarter.
Some other key findings of the survey include that expectations of a recession have shifted notably, while hiring conditions appear broadly unchanged.
In terms of the financial outlook, respondents now project revenue to grow by 2.9% over the next 12 months. The profit growth forecast is at 1.6%, according to the survey.
The research also found sentiment on the global economy has improved, with the share of executives expressing optimism rising to 25% from 22% in the prior quarter. However, it also noted that the fieldwork ended before the latest developments in the Middle East.
"Executive optimism on US economy rises in Q1 AICPA-CIMA survey" was originally created and published by The Accountant, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
View Comments
- Capstone Copper Corp. (CS:CA) Q4 2025 Earnings Call Transcript
Mar 2, 2026 · seekingalpha.com
Capstone Copper Corp. (CS:CA) Q4 2025 Earnings Call Transcript
- Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
Feb 6, 2026 · globenewswire.com
DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced positive results from the Phase 2 BEACON study evaluating brepocitinib in cutaneous sarcoidosis (CS). CS is a highly morbid, chronic, and disfiguring condition with no approved therapies, and the BEACON study is the first ever industry-sponsored placebo-controlled trial in the indication to read out positively.
- Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
Feb 6, 2026 · globenewswire.com
BASEL, Switzerland and LONDON and NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS) and reported its financial results for the third quarter ended December 31, 2025.
- ROIVANT ANNOUNCES POSITIVE PHASE 2 RESULTS FOR BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS) AND REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2025
Feb 6, 2026
BASEL, SWITZERLAND AND LONDON AND NEW YORK, FEB. 06, 2026 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY ANNOUNCED POSITIVE PHASE 2 RESULTS FOR BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS) AND REPORTED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2025.
- PRIOVANT ANNOUNCES POSITIVE PHASE 2 RESULTS FOR BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS)
Feb 6, 2026
DURHAM, N.C., FEB. 06, 2026 (GLOBE NEWSWIRE) -- PRIOVANT THERAPEUTICS TODAY ANNOUNCED POSITIVE RESULTS FROM THE PHASE 2 BEACON STUDY EVALUATING BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS). CS IS A HIGHLY MORBID, CHRONIC, AND DISFIGURING CONDITION WITH NO APPROVED THERAPIES, AND THE BEACON STUDY IS THE FIRST EVER INDUSTRY-SPONSORED PLACEBO-CONTROLLED TRIAL IN THE INDICATION TO READ OUT POSITIVELY.
- Capstone Copper Corp. (CS:CA) Q3 2025 Earnings Call Transcript
Oct 30, 2025 · seekingalpha.com
Capstone Copper Corp. ( CS:CA ) Q3 2025 Earnings Call October 30, 2025 5:00 PM EDT Company Participants Daniel Sampieri - Vice President of Investor Relations Cashel Meagher - President, CEO & Director James Whittaker Raman Randhawa - CFO & Senior VP Wendy King - Senior VP of Risk & ESG, General Counsel and Corporate Secretary Peter Amelunxen - Senior Vice President of Technical Services Conference Call Participants Ralph Profiti - Stifel Nicolaus Canada Inc., Research Division Orest Wowkodaw - Scotiabank Global Banking and Markets, Research Division Dalton Baretto - Canaccord Genuity Corp., Research Division Fahad Tariq - Jefferies LLC, Research Division Daniel Morgan - Barrenjoey Markets Pty Limited, Research Division Craig Hutchison - TD Cowen, Research Division Adam Baker - Macquarie Research Anita Soni - CIBC Capital Markets, Research Division Marcio Farid Filho - Goldman Sachs Group, Inc., Research Division Presentation Operator " Daniel Sampieri Vice President of Investor Relations " Cashel Meagher President, CEO & Director " James Whittaker " Raman Randhawa CFO & Senior VP " Wendy King Senior VP of Risk & ESG, General Counsel and Corporate Secretary " Peter Amelunxen Senior Vice President of Technical Services " Ralph Profiti Stifel Nicolaus Canada Inc., Research Division " Stifel Nicolaus Canada Inc., Research Division Orest Wowkodaw Scotiabank Global Banking and Markets, Research Division " Scotiabank Global Banking and Markets, Research Division Dalton Baretto Canaccord Genuity Corp., Research Division " Canaccord Genuity Corp., Research Division Fahad Tariq Jefferies LLC, Research Division " Jefferies LLC, Research Division Daniel Morgan Barrenjoey Markets Pty Limited, Research Division " Barrenjoey Markets Pty Limited, Research Division Craig Hutchison TD Cowen, Research Division " TD Cowen, Research Division Adam Baker Macquarie Research " Macquarie Research Anita Soni CIBC Capital Markets, Research Division " CIBC Capital Markets, Research Division Marcio Farid Filho Goldman Sachs Group, Inc., Research Division " Goldman Sachs Group, Inc., Research Division Operator
